Unlocking the Power of Cloud Supercomputing for Drug Discovery with Fovus
In the rapidly evolving landscape of computational drug discovery, cloud supercomputing is becoming an essential tool for researchers, biotech firms, and pharmaceutical companies. The ability to process large-scale molecular simulations, accelerate AI-driven research, and optimize drug development pipelines requires a computing infrastructure that is both powerful and cost-efficient.
Enter Fovus—an AI-powered, serverless HPC platform delivering intelligent, scalable, and cost-efficient supercomputing power at the scientists' and engineers' fingertips. Fovus uses AI to optimize HPC strategies and orchestrates cloud logistics, making cloud HPC a no-brainer and ensuring sustained time-cost optimality for digital innovation amid quickly evolving cloud infrastructure. By leveraging Fovus, users can execute advanced molecular dynamics tools like AlphaFold predictions out-of-box using cloud GPUs at scale efficiently, cost-effectively, and without any cloud expertise or experience needed.
Why Fovus?
Fovus is reshaping how scientists and engineers harness cloud supercomputing by providing an autonomous, AI-optimized infrastructure that removes traditional barriers to high-performance computing. With no manual cloud configuration, automatic optimization, and seamless scaling, Fovus empowers organizations to focus on discovery rather than infrastructure.
Faster Insights - Deliver computational results up to 100x faster than traditional cloud HPC approaches.
Cost Optimization - Slash cloud computing costs by up to 85% through AI-driven resource allocation.
Seamless Scalability - Dynamically adjust computing power based on real-time demand.
Simple Deployment: You can run complex workloads with a single command or a few clicks without requiring cloud expertise.
Real-World Impact
Organizations leveraging Fovus have seen tangible benefits in their research and development processes:
A leading biotech company reduced time-to-insight from weeks to hours for large-scale compound screening while cutting cloud costs by 85%.
A pharmaceutical innovator migrated 100% of its computational workloads to the cloud, boosting digital innovation productivity by 30%.
CROs like Chemspace use Fovus to optimize protein-ligand interaction studies, accelerating AI-driven computational chemistry.
Read the full Chemspace Case Study: https://www.fovus.co/case-study-chemspace/
Explore a stealth biotech success story: https://www.fovus.co/case-study-stealth-biotech-startup/
Game-Changing AI Integration: AlphaFold & Beyond
Fovus simplifies running AlphaFold 2, AlphaFold 3, and Boltz-1, allowing researchers to model protein structures at scale with minimal setup. The platform hosts all required databases and maintains containerized environments, eliminating software dependency headaches while ensuring peak efficiency.
This game-changing AI infrastructure is accelerating research in:
Drug discovery - Modeling protein-ligand interactions for better drug candidates.
Synthetic biology - Engineering novel proteins for industrial applications.
Genetic research - Understanding mutations linked to diseases.
Vaccine development - Predicting viral protein structures for faster vaccine design.
Watch how to effortlessly run AlphaFold with Fovus: https://youtu.be/90pEn35tiWY
Experience Fovus Firsthand
We’re thrilled to showcase Fovus at Drug Discovery Innovation Programme (DDIP) , where we will demonstrate the platform, connect with industry leaders, and explore new collaborations.
Interested in seeing how Fovus can transform your research? Sign up for a free trial with white-glove onboarding and experience AI-driven cloud supercomputing at its best.
Visit our website: https://www.fovus.coBook a Demo: https://www.fovus.co/get-started
Let’s unlock the full potential of cloud supercomputing for life sciences—faster, smarter, and more cost-efficient than ever before. See you at Drug Discovery Innovation Programme (DDIP)!
About Drug Discovery Innovation Programme 2025
The Drug Discovery Innovation Programme is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2025 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.